5 trials: 3 RA, 1 PsA, 1 AS | | | | | |
No. treated patients1 | 639 | 671 | 765 | 792 | 2228 |
No. SC injections | 6.6/6.0 | 42.6/57.0 | 52.9/60.0 | 45.3/61.0 | 47.1/58.0 |
Weeks of safety followup2 | 28.5/24.0 | 184.0/240.1 | 227.5/255.7 | 195.9/257.3 | 203.2/252.4 |
Total patient-yrs of followup | 350 | 2374 | 3346 | 2982 | 8702 |
Cumulative GOL dose, mg | 0.0/0.0 | 2132/2850 | 4376/4850 | 4525/6100 | 3753/3600 |
3 RA trials | | | | | |
No. treated patients1 | 449 | 374 | 542 | 565 | 1481 |
No. SC injections | 7.4/6.0 | 39.4/51.0 | 51.5/58.0 | 43.2/60.0 | 45.3/57.0 |
Weeks of safety followup2 | 32.2/24.0 | 172.0/216.3 | 223.0/252.1 | 188.3/257.0 | 196.9/244.9 |
Total patient-yrs of followup | 278 | 1237 | 2323 | 2044 | 5604 |
Cumulative GOL dose, mg | 0.0/0.0 | 1967/2525 | 4242/4625 | 4318/6000 | 3697/3650 |